Insulin Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Product Type
By: HDIN Research
Published: 2025-09-21
Pages: 101
Market Research Report Price
- Single User License (1 Users) $ 3,600
- Team License (2~5 Users) $ 4,600
- Corporate License (>5 Users) $ 5,600
Insulin Market Summary
The insulin market anchors endocrinology's therapeutic core, comprising recombinant human and analog formulations that mimic endogenous beta-cell secretion to regulate glucose homeostasis in type 1 and insulin-dependent type 2 diabetes, affecting 589 million adults in 2024 per global estimates, projected to surge 46% to 853 million by 2050 with over 90% type 2 driven by urbanization, obesity, and genetics. These injectables—basal long-acting for steady coverage, bolus fast-acting for prandial spikes, premixes for biphasic convenience, and legacy human variants—have evolved from animal extracts to biosimilar-optimized profiles achieving A1c reductions of 1-2% with hypoglycemia risks under 5%. The market's vibrancy stems from ultra-rapid analogs like Fiasp for post-meal control and smart pens integrating CGM for automated dosing, alongside oral pursuits like Rybelsus blurring GLP-1 boundaries. Biosimilars erode originator premiums 30-50%, fostering access in low-income settings where 80% unmet needs persist. By 2025, the global insulin market is estimated to be valued between USD 15 billion and USD 20 billion, with a projected compound annual growth rate (CAGR) of 2.5% to 4.5% through 2030. This solid progression aligns with IDF's prevalence forecasts, ADA/EASD guidelines prioritizing basal-bolus in youth, and payer shifts to value-based pods capping $35/day. The oligopoly of three majors holding 90% share underscores scale efficiencies, yet generics from Asia challenge with 20% cheaper human insulin. Insulin embodies diabetes' chronicity management, extending life expectancy 10 years via tight control, though adherence barriers like needle phobia affect 40%.
Regional Market Trends
Insulin market dynamics vary regionally, shaped by glycemic burdens, reimbursement tiers, and analog penetration.
● North America: Paramount with a CAGR of 2.0%–3.5%, fueled by ADA's CGM mandates and Medicare caps. The United States, the apex consumer, drives via Humalog's prandial dominance in obese cohorts, urban disparities narrowing through Lilly's affordability cards; Canada's CADTH lists prioritize long-acting glargine biosimilars.
● Europe: Balanced CAGR of 1.8%–3.0%, EMA's biosimilar incentives and NICE thresholds harmonize. Germany leads with GKV coverage for premix in migrants, United Kingdom's NHS favoring fast-acting aspart for type 1; Southern Europe's Mediterranean reversals temper growth.
● Asia-Pacific: Swiftest at CAGR 3.5%–5.0%, demographic booms and IDF's 60% share ignite. China commands with NRDL inclusions of Tonghua Dongbao's human insulin amid 140M diabetics, India's Biocon generics slashing costs 70% in rural Bihar.
● Latin America: Advancing CAGR 2.5%–4.0%, PAHO's insulin pacts and urban clinics propel. Brazil tops via SUS's Lantus tenders for type 2 epidemics, Mexico's IMSS trends premix for labor shifts.
● Middle East and Africa (MEA): Emerging CAGR 2.0%–3.5%, WHO's access models bridge. Saudi Arabia surges via SFDA's NovoLog approvals in Gulf youth, South Africa's NHIS pilots biosimilars amid 4M cases.
Type Analysis
The insulin market delineates by type, each tailored to pharmacokinetic needs and lifestyle integrations advancing closed-loop systems.
● Long-Acting Insulin: Dominant CAGR 2.5%–4.0%, basal analogs like Tresiba provide 42-hour coverage minimizing dawn phenomena, glargine's U100/U300 variants suiting pumps; trends embrace once-weekly icodec per ONWARDS, biosimilars eroding 20%.
● Premix Insulin: Stable CAGR 2.0%–3.5%, biphasic blends like Humalog Mix 75/25 simplify for novices yielding 1.5% A1c drops, human/NPH legacies in generics; evolutions probe smart cartridges for dose reminders.
● Fast-Acting Insulin: Growing CAGR 3.0%–4.5%, lispro/aspart ultra-rapids onset in 15 minutes for bolus, inhaled Afrezza niches post-meal; developments spotlight meal-detect AI in pens.
● Human Insulin: Trailing CAGR 1.5%–2.5%, recombinant regulars for affordability in LMICs, Rinsulin's vial dominance; shifts to analogs as GDP rises, generics from Zhuhai sustaining.
Company Profiles
● Novo Nordisk: Preeminent with 2024 insulin revenues of USD 8.5–9.5 billion, Tresiba and Novolog anchoring long/fast-acting; Novo's 90% share parity to rivals via Danish scale, Fiasp innovations.
● Eli Lilly: Humalog/Basaglar propelled USD 3.5–4.5 billion in 2024, biosimilar defenses in U.S.; Lilly's pipeline eyes oral insulins.
● Sanofi: Lantus/Toujeo generated USD 2.5–3.5 billion 2024, premix forte; Sanofi's EU stronghold via Admelog.
● Biocon Biologics Inc.: Indian biosimilars like Insugen capture APAC, 2024 exports booming.
● BIOTON S.A.: Polish human insulin generics for CEE affordability.
● Gan & Lee Pharmaceuticals: China's long-acting Ganlitide rivals, domestic 20% share.
● Zhuhai United Laboratories: Rinsulin vials for Africa tenders.
● Tonghua Dongbao Pharmaceutical: Premix for rural China.
● Zhejiang Hisun Pharmaceutical: Biosimilar glargine expansions.
● Fosun Wanbang Pharma Group: Fast-acting for urban diabetics.
● Wockhardt: Indian premix exports to LA.
● Julphar: UAE human insulin for MEA.
● MJ Biopharma: Korean biosimilars in Asia.
● Incepta Pharmaceuticals Ltd.: Bangladesh generics for South Asia.
Industry Value Chain Analysis
The insulin value chain melds microbial fermentation with precision delivery, from E. coli expression to adherence ecosystems. Upstream R&D engineers yeast for analog modifications via directed evolution, Novo's CRISPR tweaks yielding degludec; Phase III per ADA endpoints cost $500M, offset by orphan pediatric nods. Clinicals harness HCL trials with CGM metrics, FDA's QIDP fast-tracking biosimilars. Midstream bioprocessing cultures Pichia at 10g/L, refolding inclusion bodies for 98% purity; fill-finish in cartridges employs laser welding, Indian CMOs slashing 40%. Formulation stabilizes lispro hexamers via zinc, vials/pens serialized per DSCSA. Downstream logistics use 2-8°C hubs to pharmacies, Lilly's direct-ship mitigating shortages. Marketing deploys KOL symposia on DCCT legacies, HEOR via ICER's $50K/QALY. Support includes needle exchanges and apps like mySugr, pharmacovigilance via FAERS for lipohypertrophy. Oligopolists like Novo integrate from strain banking to RWE, fortifying against shortages.
Opportunities and Challenges
Opportunities:
● Analog Affordability: Biosimilars' 50% drops unlock 200M untreated, APAC volumes doubling per IDF.
● Closed-Loop Integrations: Pumps with insulins like Lyumjev yield 0.5% A1c gains, $5B TAM.
● Oral/Non-Injectable: Rybelsus hybrids expand adherence 30%, youth markets.
● LMIC Scaling: WHO prequals generics, halving $100B global costs by 2030.
Challenges:
● Hypoglycemia Burdens: 20% severe events demand education, curbing elderly uptake.
● Biosimilar Hesitancy: Immunogenicity fears in 10% delay switches, payer silos.
● Supply Vulnerabilities: API shortages from India/China inflate 20%, geopolitical risks.
● Adherence Gaps: 50% non-compliance in MEA via needle phobia, inflating complications $500B yearly.
The insulin market anchors endocrinology's therapeutic core, comprising recombinant human and analog formulations that mimic endogenous beta-cell secretion to regulate glucose homeostasis in type 1 and insulin-dependent type 2 diabetes, affecting 589 million adults in 2024 per global estimates, projected to surge 46% to 853 million by 2050 with over 90% type 2 driven by urbanization, obesity, and genetics. These injectables—basal long-acting for steady coverage, bolus fast-acting for prandial spikes, premixes for biphasic convenience, and legacy human variants—have evolved from animal extracts to biosimilar-optimized profiles achieving A1c reductions of 1-2% with hypoglycemia risks under 5%. The market's vibrancy stems from ultra-rapid analogs like Fiasp for post-meal control and smart pens integrating CGM for automated dosing, alongside oral pursuits like Rybelsus blurring GLP-1 boundaries. Biosimilars erode originator premiums 30-50%, fostering access in low-income settings where 80% unmet needs persist. By 2025, the global insulin market is estimated to be valued between USD 15 billion and USD 20 billion, with a projected compound annual growth rate (CAGR) of 2.5% to 4.5% through 2030. This solid progression aligns with IDF's prevalence forecasts, ADA/EASD guidelines prioritizing basal-bolus in youth, and payer shifts to value-based pods capping $35/day. The oligopoly of three majors holding 90% share underscores scale efficiencies, yet generics from Asia challenge with 20% cheaper human insulin. Insulin embodies diabetes' chronicity management, extending life expectancy 10 years via tight control, though adherence barriers like needle phobia affect 40%.
Regional Market Trends
Insulin market dynamics vary regionally, shaped by glycemic burdens, reimbursement tiers, and analog penetration.
● North America: Paramount with a CAGR of 2.0%–3.5%, fueled by ADA's CGM mandates and Medicare caps. The United States, the apex consumer, drives via Humalog's prandial dominance in obese cohorts, urban disparities narrowing through Lilly's affordability cards; Canada's CADTH lists prioritize long-acting glargine biosimilars.
● Europe: Balanced CAGR of 1.8%–3.0%, EMA's biosimilar incentives and NICE thresholds harmonize. Germany leads with GKV coverage for premix in migrants, United Kingdom's NHS favoring fast-acting aspart for type 1; Southern Europe's Mediterranean reversals temper growth.
● Asia-Pacific: Swiftest at CAGR 3.5%–5.0%, demographic booms and IDF's 60% share ignite. China commands with NRDL inclusions of Tonghua Dongbao's human insulin amid 140M diabetics, India's Biocon generics slashing costs 70% in rural Bihar.
● Latin America: Advancing CAGR 2.5%–4.0%, PAHO's insulin pacts and urban clinics propel. Brazil tops via SUS's Lantus tenders for type 2 epidemics, Mexico's IMSS trends premix for labor shifts.
● Middle East and Africa (MEA): Emerging CAGR 2.0%–3.5%, WHO's access models bridge. Saudi Arabia surges via SFDA's NovoLog approvals in Gulf youth, South Africa's NHIS pilots biosimilars amid 4M cases.
Type Analysis
The insulin market delineates by type, each tailored to pharmacokinetic needs and lifestyle integrations advancing closed-loop systems.
● Long-Acting Insulin: Dominant CAGR 2.5%–4.0%, basal analogs like Tresiba provide 42-hour coverage minimizing dawn phenomena, glargine's U100/U300 variants suiting pumps; trends embrace once-weekly icodec per ONWARDS, biosimilars eroding 20%.
● Premix Insulin: Stable CAGR 2.0%–3.5%, biphasic blends like Humalog Mix 75/25 simplify for novices yielding 1.5% A1c drops, human/NPH legacies in generics; evolutions probe smart cartridges for dose reminders.
● Fast-Acting Insulin: Growing CAGR 3.0%–4.5%, lispro/aspart ultra-rapids onset in 15 minutes for bolus, inhaled Afrezza niches post-meal; developments spotlight meal-detect AI in pens.
● Human Insulin: Trailing CAGR 1.5%–2.5%, recombinant regulars for affordability in LMICs, Rinsulin's vial dominance; shifts to analogs as GDP rises, generics from Zhuhai sustaining.
Company Profiles
● Novo Nordisk: Preeminent with 2024 insulin revenues of USD 8.5–9.5 billion, Tresiba and Novolog anchoring long/fast-acting; Novo's 90% share parity to rivals via Danish scale, Fiasp innovations.
● Eli Lilly: Humalog/Basaglar propelled USD 3.5–4.5 billion in 2024, biosimilar defenses in U.S.; Lilly's pipeline eyes oral insulins.
● Sanofi: Lantus/Toujeo generated USD 2.5–3.5 billion 2024, premix forte; Sanofi's EU stronghold via Admelog.
● Biocon Biologics Inc.: Indian biosimilars like Insugen capture APAC, 2024 exports booming.
● BIOTON S.A.: Polish human insulin generics for CEE affordability.
● Gan & Lee Pharmaceuticals: China's long-acting Ganlitide rivals, domestic 20% share.
● Zhuhai United Laboratories: Rinsulin vials for Africa tenders.
● Tonghua Dongbao Pharmaceutical: Premix for rural China.
● Zhejiang Hisun Pharmaceutical: Biosimilar glargine expansions.
● Fosun Wanbang Pharma Group: Fast-acting for urban diabetics.
● Wockhardt: Indian premix exports to LA.
● Julphar: UAE human insulin for MEA.
● MJ Biopharma: Korean biosimilars in Asia.
● Incepta Pharmaceuticals Ltd.: Bangladesh generics for South Asia.
Industry Value Chain Analysis
The insulin value chain melds microbial fermentation with precision delivery, from E. coli expression to adherence ecosystems. Upstream R&D engineers yeast for analog modifications via directed evolution, Novo's CRISPR tweaks yielding degludec; Phase III per ADA endpoints cost $500M, offset by orphan pediatric nods. Clinicals harness HCL trials with CGM metrics, FDA's QIDP fast-tracking biosimilars. Midstream bioprocessing cultures Pichia at 10g/L, refolding inclusion bodies for 98% purity; fill-finish in cartridges employs laser welding, Indian CMOs slashing 40%. Formulation stabilizes lispro hexamers via zinc, vials/pens serialized per DSCSA. Downstream logistics use 2-8°C hubs to pharmacies, Lilly's direct-ship mitigating shortages. Marketing deploys KOL symposia on DCCT legacies, HEOR via ICER's $50K/QALY. Support includes needle exchanges and apps like mySugr, pharmacovigilance via FAERS for lipohypertrophy. Oligopolists like Novo integrate from strain banking to RWE, fortifying against shortages.
Opportunities and Challenges
Opportunities:
● Analog Affordability: Biosimilars' 50% drops unlock 200M untreated, APAC volumes doubling per IDF.
● Closed-Loop Integrations: Pumps with insulins like Lyumjev yield 0.5% A1c gains, $5B TAM.
● Oral/Non-Injectable: Rybelsus hybrids expand adherence 30%, youth markets.
● LMIC Scaling: WHO prequals generics, halving $100B global costs by 2030.
Challenges:
● Hypoglycemia Burdens: 20% severe events demand education, curbing elderly uptake.
● Biosimilar Hesitancy: Immunogenicity fears in 10% delay switches, payer silos.
● Supply Vulnerabilities: API shortages from India/China inflate 20%, geopolitical risks.
● Adherence Gaps: 50% non-compliance in MEA via needle phobia, inflating complications $500B yearly.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Insulin Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Insulin Market in North America (2020-2030)
8.1 Insulin Market Size
8.2 Insulin Market by End Use
8.3 Competition by Players/Suppliers
8.4 Insulin Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Insulin Market in South America (2020-2030)
9.1 Insulin Market Size
9.2 Insulin Market by End Use
9.3 Competition by Players/Suppliers
9.4 Insulin Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Insulin Market in Asia & Pacific (2020-2030)
10.1 Insulin Market Size
10.2 Insulin Market by End Use
10.3 Competition by Players/Suppliers
10.4 Insulin Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Insulin Market in Europe (2020-2030)
11.1 Insulin Market Size
11.2 Insulin Market by End Use
11.3 Competition by Players/Suppliers
11.4 Insulin Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Insulin Market in MEA (2020-2030)
12.1 Insulin Market Size
12.2 Insulin Market by End Use
12.3 Competition by Players/Suppliers
12.4 Insulin Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Insulin Market (2020-2025)
13.1 Insulin Market Size
13.2 Insulin Market by End Use
13.3 Competition by Players/Suppliers
13.4 Insulin Market Size by Type
Chapter 14 Global Insulin Market Forecast (2025-2030)
14.1 Insulin Market Size Forecast
14.2 Insulin Application Forecast
14.3 Competition by Players/Suppliers
14.4 Insulin Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Novo Nordisk
15.1.1 Company Profile
15.1.2 Main Business and Insulin Information
15.1.3 SWOT Analysis of Novo Nordisk
15.1.4 Novo Nordisk Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.2 Eli Lilly
15.2.1 Company Profile
15.2.2 Main Business and Insulin Information
15.2.3 SWOT Analysis of Eli Lilly
15.2.4 Eli Lilly Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.3 Sanofi
15.3.1 Company Profile
15.3.2 Main Business and Insulin Information
15.3.3 SWOT Analysis of Sanofi
15.3.4 Sanofi Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.4 Biocon Biologics Inc.
15.4.1 Company Profile
15.4.2 Main Business and Insulin Information
15.4.3 SWOT Analysis of Biocon Biologics Inc.
15.4.4 Biocon Biologics Inc. Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.5 BIOTON S.A.
15.5.1 Company Profile
15.5.2 Main Business and Insulin Information
15.5.3 SWOT Analysis of BIOTON S.A.
15.5.4 BIOTON S.A. Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.6 Gan & Lee Pharmaceuticals
15.6.1 Company Profile
15.6.2 Main Business and Insulin Information
15.6.3 SWOT Analysis of Gan & Lee Pharmaceuticals
15.6.4 Gan & Lee Pharmaceuticals Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.7 Zhuhai United Laboratories
15.7.1 Company Profile
15.7.2 Main Business and Insulin Information
15.7.3 SWOT Analysis of Zhuhai United Laboratories
15.7.4 Zhuhai United Laboratories Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.8 Tonghua Dongbao Pharmaceutical
15.8.1 Company Profile
15.8.2 Main Business and Insulin Information
15.8.3 SWOT Analysis of Tonghua Dongbao Pharmaceutical
15.8.4 Tonghua Dongbao Pharmaceutical Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.9 Zhejiang Hisun Pharmaceutical
15.9.1 Company Profile
15.9.2 Main Business and Insulin Information
15.9.3 SWOT Analysis of Zhejiang Hisun Pharmaceutical
15.9.4 Zhejiang Hisun Pharmaceutical Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.10 Fosun Wanbang Pharma Group
15.10.1 Company Profile
15.10.2 Main Business and Insulin Information
15.10.3 SWOT Analysis of Fosun Wanbang Pharma Group
15.10.4 Fosun Wanbang Pharma Group Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.11 Wockhardt
15.11.1 Company Profile
15.11.2 Main Business and Insulin Information
15.11.3 SWOT Analysis of Wockhardt
15.11.4 Wockhardt Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.12 Julphar
15.12.1 Company Profile
15.12.2 Main Business and Insulin Information
15.12.3 SWOT Analysis of Julphar
15.12.4 Julphar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
Please ask for sample pages for full companies list
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Insulin Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Insulin Market in North America (2020-2030)
8.1 Insulin Market Size
8.2 Insulin Market by End Use
8.3 Competition by Players/Suppliers
8.4 Insulin Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Insulin Market in South America (2020-2030)
9.1 Insulin Market Size
9.2 Insulin Market by End Use
9.3 Competition by Players/Suppliers
9.4 Insulin Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Insulin Market in Asia & Pacific (2020-2030)
10.1 Insulin Market Size
10.2 Insulin Market by End Use
10.3 Competition by Players/Suppliers
10.4 Insulin Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Insulin Market in Europe (2020-2030)
11.1 Insulin Market Size
11.2 Insulin Market by End Use
11.3 Competition by Players/Suppliers
11.4 Insulin Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Insulin Market in MEA (2020-2030)
12.1 Insulin Market Size
12.2 Insulin Market by End Use
12.3 Competition by Players/Suppliers
12.4 Insulin Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Insulin Market (2020-2025)
13.1 Insulin Market Size
13.2 Insulin Market by End Use
13.3 Competition by Players/Suppliers
13.4 Insulin Market Size by Type
Chapter 14 Global Insulin Market Forecast (2025-2030)
14.1 Insulin Market Size Forecast
14.2 Insulin Application Forecast
14.3 Competition by Players/Suppliers
14.4 Insulin Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Novo Nordisk
15.1.1 Company Profile
15.1.2 Main Business and Insulin Information
15.1.3 SWOT Analysis of Novo Nordisk
15.1.4 Novo Nordisk Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.2 Eli Lilly
15.2.1 Company Profile
15.2.2 Main Business and Insulin Information
15.2.3 SWOT Analysis of Eli Lilly
15.2.4 Eli Lilly Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.3 Sanofi
15.3.1 Company Profile
15.3.2 Main Business and Insulin Information
15.3.3 SWOT Analysis of Sanofi
15.3.4 Sanofi Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.4 Biocon Biologics Inc.
15.4.1 Company Profile
15.4.2 Main Business and Insulin Information
15.4.3 SWOT Analysis of Biocon Biologics Inc.
15.4.4 Biocon Biologics Inc. Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.5 BIOTON S.A.
15.5.1 Company Profile
15.5.2 Main Business and Insulin Information
15.5.3 SWOT Analysis of BIOTON S.A.
15.5.4 BIOTON S.A. Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.6 Gan & Lee Pharmaceuticals
15.6.1 Company Profile
15.6.2 Main Business and Insulin Information
15.6.3 SWOT Analysis of Gan & Lee Pharmaceuticals
15.6.4 Gan & Lee Pharmaceuticals Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.7 Zhuhai United Laboratories
15.7.1 Company Profile
15.7.2 Main Business and Insulin Information
15.7.3 SWOT Analysis of Zhuhai United Laboratories
15.7.4 Zhuhai United Laboratories Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.8 Tonghua Dongbao Pharmaceutical
15.8.1 Company Profile
15.8.2 Main Business and Insulin Information
15.8.3 SWOT Analysis of Tonghua Dongbao Pharmaceutical
15.8.4 Tonghua Dongbao Pharmaceutical Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.9 Zhejiang Hisun Pharmaceutical
15.9.1 Company Profile
15.9.2 Main Business and Insulin Information
15.9.3 SWOT Analysis of Zhejiang Hisun Pharmaceutical
15.9.4 Zhejiang Hisun Pharmaceutical Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.10 Fosun Wanbang Pharma Group
15.10.1 Company Profile
15.10.2 Main Business and Insulin Information
15.10.3 SWOT Analysis of Fosun Wanbang Pharma Group
15.10.4 Fosun Wanbang Pharma Group Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.11 Wockhardt
15.11.1 Company Profile
15.11.2 Main Business and Insulin Information
15.11.3 SWOT Analysis of Wockhardt
15.11.4 Wockhardt Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
15.12 Julphar
15.12.1 Company Profile
15.12.2 Main Business and Insulin Information
15.12.3 SWOT Analysis of Julphar
15.12.4 Julphar Insulin Sales, Revenue, Price and Gross Margin (2020-2025)
Please ask for sample pages for full companies list
Table Abbreviation and Acronyms
Table Research Scope of Insulin Report
Table Data Sources of Insulin Report
Table Major Assumptions of Insulin Report
Table Insulin Classification
Table Insulin Applications
Table Drivers of Insulin Market
Table Restraints of Insulin Market
Table Opportunities of Insulin Market
Table Threats of Insulin Market
Table Raw Materials Suppliers
Table Different Production Methods of Insulin
Table Cost Structure Analysis of Insulin
Table Key End Users
Table Latest News of Insulin Market
Table Merger and Acquisition
Table Planned/Future Project of Insulin Market
Table Policy of Insulin Market
Table 2020-2030 North America Insulin Market Size
Table 2020-2030 North America Insulin Market Size by Application
Table 2020-2025 North America Insulin Key Players Revenue
Table 2020-2025 North America Insulin Key Players Market Share
Table 2020-2030 North America Insulin Market Size by Type
Table 2020-2030 United States Insulin Market Size
Table 2020-2030 Canada Insulin Market Size
Table 2020-2030 Mexico Insulin Market Size
Table 2020-2030 South America Insulin Market Size
Table 2020-2030 South America Insulin Market Size by Application
Table 2020-2025 South America Insulin Key Players Revenue
Table 2020-2025 South America Insulin Key Players Market Share
Table 2020-2030 South America Insulin Market Size by Type
Table 2020-2030 Brazil Insulin Market Size
Table 2020-2030 Argentina Insulin Market Size
Table 2020-2030 Chile Insulin Market Size
Table 2020-2030 Peru Insulin Market Size
Table 2020-2030 Asia & Pacific Insulin Market Size
Table 2020-2030 Asia & Pacific Insulin Market Size by Application
Table 2020-2025 Asia & Pacific Insulin Key Players Revenue
Table 2020-2025 Asia & Pacific Insulin Key Players Market Share
Table 2020-2030 Asia & Pacific Insulin Market Size by Type
Table 2020-2030 China Insulin Market Size
Table 2020-2030 India Insulin Market Size
Table 2020-2030 Japan Insulin Market Size
Table 2020-2030 South Korea Insulin Market Size
Table 2020-2030 Southeast Asia Insulin Market Size
Table 2020-2030 Australia Insulin Market Size
Table 2020-2030 Europe Insulin Market Size
Table 2020-2030 Europe Insulin Market Size by Application
Table 2020-2025 Europe Insulin Key Players Revenue
Table 2020-2025 Europe Insulin Key Players Market Share
Table 2020-2030 Europe Insulin Market Size by Type
Table 2020-2030 Germany Insulin Market Size
Table 2020-2030 France Insulin Market Size
Table 2020-2030 United Kingdom Insulin Market Size
Table 2020-2030 Italy Insulin Market Size
Table 2020-2030 Spain Insulin Market Size
Table 2020-2030 Belgium Insulin Market Size
Table 2020-2030 Netherlands Insulin Market Size
Table 2020-2030 Austria Insulin Market Size
Table 2020-2030 Poland Insulin Market Size
Table 2020-2030 Russia Insulin Market Size
Table 2020-2030 MEA Insulin Market Size
Table 2020-2030 MEA Insulin Market Size by Application
Table 2020-2025 MEA Insulin Key Players Revenue
Table 2020-2025 MEA Insulin Key Players Market Share
Table 2020-2030 MEA Insulin Market Size by Type
Table 2020-2030 Egypt Insulin Market Size
Table 2020-2030 Israel Insulin Market Size
Table 2020-2030 South Africa Insulin Market Size
Table 2020-2030 Gulf Cooperation Council Countries Insulin Market Size
Table 2020-2030 Turkey Insulin Market Size
Table 2020-2025 Global Insulin Market Size by Region
Table 2020-2025 Global Insulin Market Size Share by Region
Table 2020-2025 Global Insulin Market Size by Application
Table 2020-2025 Global Insulin Market Share by Application
Table 2020-2025 Global Insulin Key Vendors Revenue
Table 2020-2025 Global Insulin Key Vendors Market Share
Table 2020-2025 Global Insulin Market Size by Type
Table 2020-2025 Global Insulin Market Share by Type
Table 2025-2030 Global Insulin Market Size by Region
Table 2025-2030 Global Insulin Market Size Share by Region
Table 2025-2030 Global Insulin Market Size by Application
Table 2025-2030 Global Insulin Market Share by Application
Table 2025-2030 Global Insulin Key Vendors Revenue
Table 2025-2030 Global Insulin Key Vendors Market Share
Table 2025-2030 Global Insulin Market Size by Type
Table 2025-2030 Insulin Global Market Share by Type
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Insulin Picture
Figure 2020-2030 North America Insulin Market Size and CAGR
Figure 2020-2030 South America Insulin Market Size and CAGR
Figure 2020-2030 Asia & Pacific Insulin Market Size and CAGR
Figure 2020-2030 Europe Insulin Market Size and CAGR
Figure 2020-2030 MEA Insulin Market Size and CAGR
Figure 2020-2025 Global Insulin Market Size and Growth Rate
Figure 2025-2030 Global Insulin Market Size and Growth Rate
Table Research Scope of Insulin Report
Table Data Sources of Insulin Report
Table Major Assumptions of Insulin Report
Table Insulin Classification
Table Insulin Applications
Table Drivers of Insulin Market
Table Restraints of Insulin Market
Table Opportunities of Insulin Market
Table Threats of Insulin Market
Table Raw Materials Suppliers
Table Different Production Methods of Insulin
Table Cost Structure Analysis of Insulin
Table Key End Users
Table Latest News of Insulin Market
Table Merger and Acquisition
Table Planned/Future Project of Insulin Market
Table Policy of Insulin Market
Table 2020-2030 North America Insulin Market Size
Table 2020-2030 North America Insulin Market Size by Application
Table 2020-2025 North America Insulin Key Players Revenue
Table 2020-2025 North America Insulin Key Players Market Share
Table 2020-2030 North America Insulin Market Size by Type
Table 2020-2030 United States Insulin Market Size
Table 2020-2030 Canada Insulin Market Size
Table 2020-2030 Mexico Insulin Market Size
Table 2020-2030 South America Insulin Market Size
Table 2020-2030 South America Insulin Market Size by Application
Table 2020-2025 South America Insulin Key Players Revenue
Table 2020-2025 South America Insulin Key Players Market Share
Table 2020-2030 South America Insulin Market Size by Type
Table 2020-2030 Brazil Insulin Market Size
Table 2020-2030 Argentina Insulin Market Size
Table 2020-2030 Chile Insulin Market Size
Table 2020-2030 Peru Insulin Market Size
Table 2020-2030 Asia & Pacific Insulin Market Size
Table 2020-2030 Asia & Pacific Insulin Market Size by Application
Table 2020-2025 Asia & Pacific Insulin Key Players Revenue
Table 2020-2025 Asia & Pacific Insulin Key Players Market Share
Table 2020-2030 Asia & Pacific Insulin Market Size by Type
Table 2020-2030 China Insulin Market Size
Table 2020-2030 India Insulin Market Size
Table 2020-2030 Japan Insulin Market Size
Table 2020-2030 South Korea Insulin Market Size
Table 2020-2030 Southeast Asia Insulin Market Size
Table 2020-2030 Australia Insulin Market Size
Table 2020-2030 Europe Insulin Market Size
Table 2020-2030 Europe Insulin Market Size by Application
Table 2020-2025 Europe Insulin Key Players Revenue
Table 2020-2025 Europe Insulin Key Players Market Share
Table 2020-2030 Europe Insulin Market Size by Type
Table 2020-2030 Germany Insulin Market Size
Table 2020-2030 France Insulin Market Size
Table 2020-2030 United Kingdom Insulin Market Size
Table 2020-2030 Italy Insulin Market Size
Table 2020-2030 Spain Insulin Market Size
Table 2020-2030 Belgium Insulin Market Size
Table 2020-2030 Netherlands Insulin Market Size
Table 2020-2030 Austria Insulin Market Size
Table 2020-2030 Poland Insulin Market Size
Table 2020-2030 Russia Insulin Market Size
Table 2020-2030 MEA Insulin Market Size
Table 2020-2030 MEA Insulin Market Size by Application
Table 2020-2025 MEA Insulin Key Players Revenue
Table 2020-2025 MEA Insulin Key Players Market Share
Table 2020-2030 MEA Insulin Market Size by Type
Table 2020-2030 Egypt Insulin Market Size
Table 2020-2030 Israel Insulin Market Size
Table 2020-2030 South Africa Insulin Market Size
Table 2020-2030 Gulf Cooperation Council Countries Insulin Market Size
Table 2020-2030 Turkey Insulin Market Size
Table 2020-2025 Global Insulin Market Size by Region
Table 2020-2025 Global Insulin Market Size Share by Region
Table 2020-2025 Global Insulin Market Size by Application
Table 2020-2025 Global Insulin Market Share by Application
Table 2020-2025 Global Insulin Key Vendors Revenue
Table 2020-2025 Global Insulin Key Vendors Market Share
Table 2020-2025 Global Insulin Market Size by Type
Table 2020-2025 Global Insulin Market Share by Type
Table 2025-2030 Global Insulin Market Size by Region
Table 2025-2030 Global Insulin Market Size Share by Region
Table 2025-2030 Global Insulin Market Size by Application
Table 2025-2030 Global Insulin Market Share by Application
Table 2025-2030 Global Insulin Key Vendors Revenue
Table 2025-2030 Global Insulin Key Vendors Market Share
Table 2025-2030 Global Insulin Market Size by Type
Table 2025-2030 Insulin Global Market Share by Type
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Insulin Picture
Figure 2020-2030 North America Insulin Market Size and CAGR
Figure 2020-2030 South America Insulin Market Size and CAGR
Figure 2020-2030 Asia & Pacific Insulin Market Size and CAGR
Figure 2020-2030 Europe Insulin Market Size and CAGR
Figure 2020-2030 MEA Insulin Market Size and CAGR
Figure 2020-2025 Global Insulin Market Size and Growth Rate
Figure 2025-2030 Global Insulin Market Size and Growth Rate
Research Methodology
- Market Estimated Methodology:
Bottom-up & top-down approach, supply & demand approach are the most important method which is used by HDIN Research to estimate the market size.
1）Top-down & Bottom-up Approach
Top-down approach uses a general market size figure and determines the percentage that the objective market represents.
Bottom-up approach size the objective market by collecting the sub-segment information.
2）Supply & Demand Approach
Supply approach is based on assessments of the size of each competitor supplying the objective market.
Demand approach combine end-user data within a market to estimate the objective market size. It is sometimes referred to as bottom-up approach.
- Forecasting Methodology
- Numerous factors impacting the market trend are considered for forecast model:
- New technology and application in the future;
- New project planned/under contraction;
- Global and regional underlying economic growth;
- Threatens of substitute products;
- Industry expert opinion;
- Policy and Society implication.
- Analysis Tools
1）PEST Analysis
PEST Analysis is a simple and widely used tool that helps our client analyze the Political, Economic, Socio-Cultural, and Technological changes in their business environment.
- Benefits of a PEST analysis:
- It helps you to spot business opportunities, and it gives you advanced warning of significant threats.
- It reveals the direction of change within your business environment. This helps you shape what you’re doing, so that you work with change, rather than against it.
- It helps you avoid starting projects that are likely to fail, for reasons beyond your control.
- It can help you break free of unconscious assumptions when you enter a new country, region, or market; because it helps you develop an objective view of this new environment.
2）Porter’s Five Force Model Analysis
The Porter’s Five Force Model is a tool that can be used to analyze the opportunities and overall competitive advantage. The five forces that can assist in determining the competitive intensity and potential attractiveness within a specific area.
- Threat of New Entrants: Profitable industries that yield high returns will attract new firms.
- Threat of Substitutes: A substitute product uses a different technology to try to solve the same economic need.
- Bargaining Power of Customers: the ability of customers to put the firm under pressure, which also affects the customer's sensitivity to price changes.
- Bargaining Power of Suppliers: Suppliers of raw materials, components, labor, and services (such as expertise) to the firm can be a source of power over the firm when there are few substitutes.
- Competitive Rivalry: For most industries the intensity of competitive rivalry is the major determinant of the competitiveness of the industry.
3）Value Chain Analysis
Value chain analysis is a tool to identify activities, within and around the firm and relating these activities to an assessment of competitive strength. Value chain can be analyzed by primary activities and supportive activities. Primary activities include: inbound logistics, operations, outbound logistics, marketing & sales, service. Support activities include: technology development, human resource management, management, finance, legal, planning.
4）SWOT Analysis
SWOT analysis is a tool used to evaluate a company's competitive position by identifying its strengths, weaknesses, opportunities and threats. The strengths and weakness is the inner factor; the opportunities and threats are the external factor. By analyzing the inner and external factors, the analysis can provide the detail information of the position of a player and the characteristics of the industry.
- Strengths describe what the player excels at and separates it from the competition
- Weaknesses stop the player from performing at its optimum level.
- Opportunities refer to favorable external factors that the player can use to give it a competitive advantage.
- Threats refer to factors that have the potential to harm the player.
- Data Sources
| Primary Sources | Secondary Sources |
|---|---|
| Face to face/Phone Interviews with market participants, such as: Manufactures; Distributors; End-users; Experts. Online Survey |
Government/International Organization Data: Annual Report/Presentation/Fact Book Internet Source Information Industry Association Data Free/Purchased Database Market Research Report Book/Journal/News |